IGF1R and neoplasm: Future modifications to siRNAs targeting IGF-1R may improve their effectiveness in downregulating IGF-1R and modulating anti-tumor immune responses, potentially offering new clinical approaches for treating mammary tumors expressing IGF-1R [149].